Literature DB >> 1717553

Monoclonal antibodies to the calcium-binding region peptide of human C-reactive protein alter its conformation.

S J Swanson1, M C Mullenix, R F Mortensen.   

Abstract

Five mouse mAb were generated against a synthetic peptide corresponding to the proposed Ca(2+)-binding region of human C-reactive protein (CRP). The peptide consists of amino acids 134 to 148 and possesses a calmodulin Ca(2+)-binding sequence. The mAb reacted with a surface epitope(s) on native, intact CRP as well as the closely related pentraxin protein, serum amyloid P-component. Three of the 5 mAb inhibited the Ca(2+)-dependent phosphorylcholine-(PC) binding activity of CRP, but did not bind to the PC-binding region itself. Four of the five mAb also inhibited the recognition of an epitope in the PC-binding site of CRP. Four of the mAb partially, or completely, protected CRP from selective cleavage by pronase between residues 146 and 147. The findings suggest that the Ca(2+)-binding region is on the surface of CRP, has substantial flexibility, and is probably responsible for the allosteric effects of Ca2+ ions on CRP.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717553

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Reactivity of anti-human C-reactive protein (CRP) and serum amyloid P component (SAP) monoclonal antibodies with limulin and pentraxins of other species.

Authors:  S C Ying; J J Marchalonis; A T Gewurz; J N Siegel; H Jiang; B E Gewurz; H Gewurz
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

2.  A protease-sensitive site in the proposed Ca(2+)-binding region of human serum amyloid P component and other pentraxins.

Authors:  C M Kinoshita; A T Gewurz; J N Siegel; S C Ying; T E Hugli; J E Coe; R K Gupta; R Huckman; H Gewurz
Journal:  Protein Sci       Date:  1992-06       Impact factor: 6.725

Review 3.  C-Reactive Protein and Cancer: Interpreting the Differential Bioactivities of Its Pentameric and Monomeric, Modified Isoforms.

Authors:  Lawrence A Potempa; Ibraheem M Rajab; Margaret E Olson; Peter C Hart
Journal:  Front Immunol       Date:  2021-09-06       Impact factor: 7.561

Review 4.  How C-Reactive Protein Structural Isoforms With Distinctive Bioactivities Affect Disease Progression.

Authors:  Ibraheem M Rajab; Peter C Hart; Lawrence A Potempa
Journal:  Front Immunol       Date:  2020-09-10       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.